To report a case of choroidal neovascularisation and leakage in a myopic female predicted to be a choroideraemia carrier treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF).
Methods:
Case report.
Results:
A female magazine editor presented with sudden decrease in vision in her right eye, with Snellen visual acuities (VAs) of 1/60 and 3/60 in the right and left eyes respectively. She was diagnosed with choroidal neovascularisation (CNV) formation and subretinal haemorrhage in her right eye. This is on a background of previous presentations, the first of which was 20 years ago for declining left eye vision. She was subsequently found to be a predicted choroideraemia carrier. However, she also has high myopia, and it is unclear whether the predicted choroideraemia carrier status or high myopia is the main underlying cause of her CNV, although we believe that the former is more likely. The first episode of CNV in her right eye was treated successfully with intravitreal anti-VEGF. However, she experienced four further CNV reactivations in her right eye, all of which were treated successfully with anti-VEGF. At her last follow-up visit to date, Snellen VAs were 6/9 and 3/60 in her right and left eye respectively.
Conclusion:
This is a unique case of CNV formation in a predicted choroideraemia carrier who also has co-existent high myopia. Prompt treatment of CNV activity with anti-VEGF has been efficacious in prevention of subretinal fibrosis and irreversible vision loss and allowed the patient to continue working in her chosen career.
ChengJLFarnsworthKBernsteinPS. Choroideremia in a woman with turner syndrome. JAMA Ophthalmol2018; 136(9): 1076–1078.
2.
MukkamalaKGentileRCWillnerJ, et al. Choroideremia in a woman with ectodermal dysplasia and complex translocations involving chromosomes X, 1, and 3. Ophthalmic Genet2010; 31(4): 178–182.
3.
ImaniSIjazIShasaltanehMD, et al. Molecular genetics characterization and homology modeling of the CHM gene mutation: a study on its association with choroideremia. Mutat Res2018; 775: 39–50.
4.
MitsiosADubisAMMoosajeeM. Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments. Ther Adv Ophthalmol2018; 10: 1–18.
5.
RobertsMFFishmanGARobertsDK, et al. Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia. Br J Ophthalmol2002; 86(6): 658–662.
6.
CoussaRGKimJTraboulsiEI. Choroideremia: effect of age on visual acuity in patients and female carriers. Ophthalmic Genet2012; 33(2): 66–73.
7.
RennerABKellnerUCroppE, et al. Choroideremia: variability of clinical and electrophysiological characteristics and first report of a negative electroretinogram. Ophthalmology2006; 113(11): 2066.e1–10.
8.
SimunovicMPJollyJKXueK, et al. The spectrum of CHM gene mutations in choroideremia and their relationship to clinical phenotype. Invest Ophthalmol Vis Sci2016; 57(14): 6033–6039.
9.
BozbeyogluSFishmanGAStoneEM, et al. De novo mutation in a choroideremia carrier. Retin Cases Brief Rep2007; 1(3): 182–184.
10.
PotterMJWongESzaboSM, et al. Clinical findings in a carrier of a new mutation in the choroideremia gene. Ophthalmology2004; 111(10): 1905–1909.
RobinsonDTiedemanJ. Choroideremia associated with a subretinal neovascular membrane. Case report. Retina1987; 7(2): 70–74.
13.
PalejwalaNVLauerAKWeleberRG. Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab. Clin Ophthalmol2014; 8: 1675–1679.
14.
SawaMTamakiYKlancnikJMJr, et al. Intraretinal foveal neovascularization in choroideremia. Retina2006; 26(5): 585–588.
15.
RudolphGPreisingMKalpadakisP, et al. Phenotypic variability in three carriers from a family with choroideremia and a frameshift mutation 1388delCCinsG in the REP-1 gene. Ophthalmic Genet2003; 24(4): 203–214.
16.
MacDonaldIMRussellLChanC-C. Choroideremia: new findings from ocular pathology and review of recent literature. Surv Ophthalmol2009; 54(3): 401–407.
17.
CameronJDFineBSShapiroI. Histopathologic observations in choroideremia with emphasis on vascular changes of the uveal tract. Ophthalmology1987; 94(2): 187–196.
18.
CohenSYLarocheALeguenY, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology1996; 103(8): 1241–1244.
19.
GrossniklausHEGassJD. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol1998; 126(1): 59–69.
20.
GrossniklausHEGreenWR. Choroidal neovascularization. Am J Ophthalmol2004; 137(3): 496–503.
21.
CarneiroAMSilvaRMVeludoMJ, et al. Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. Ophthalmologica2011; 225(2): 81–88.
22.
SivaprasadSMooreAT. Choroidal neovascularisation in children. Br J Ophthalmol2008; 92(4): 451–454.
HeierJSBoyerDSCiullaTA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol2006; 124(11): 1532–1542.
25.
AntoszykANTuomiLChungCY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol2008; 145(5): 862–874.
26.
BrownDMMichelsMKaiserPK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology2009; 116(1): 57–65.e5.
27.
HolzFGAmoakuWDonateJ, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology2011; 118(4): 663–671.
28.
TufailANarendranNPatelPJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology2013; 120(9): 1944–5.e1.
29.
WolfSBalciunieneVJLaganovskaG, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology2014; 121(3): 682–92.e2.
30.
KangHMKohHJ. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization. Am J Ophthalmol2013; 155(4): 713–719, 9.e1.
31.
ParodiMBIaconoPKontadakisDS, et al. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Arch Ophthalmol2010; 128(9): 1100–1103.
32.
CornishKSWilliamsGJGavinMP, et al. Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy. Eur J Ophthalmol2011; 21(4): 440–445.
33.
LaiTYYStaurenghiGLanzettaP, et al. Efficacy and safety of Ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina2018; 38(8): 1464–1477.
34.
FerraraNDamicoLShamsN, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina2006; 26(8): 859–870.
35.
TongJPChanWMLiuDT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol2006; 141(3): 456–462.
36.
OtaniATakagiHOhH, et al. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci1999; 40(9): 1912–1920.
37.
ZhouPYangLJinX. Ranibizumab versus bevacizumab for the treatment of idiopathic choroidal neovascularization: 2-year results. Eur J Ophthalmol2016; 26(3): 262–267.
